Consensus LivaNova PLC Börse Stuttgart

Stocks

LIA

GB00BYMT0J19

Medical Equipment, Supplies & Distribution

Market Closed - Börse Stuttgart 15:56:18 2026-09-18 EDT			5-day change	1st Jan Change
67.50 ^EUR	0.00%		0.00%	+28.57%

09-14	Livanova Insider Sold Shares Worth $273,032, According to a Recent SEC Filing	MT
09-14	LivaNova PLC Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 11:30 AM

4ad7c2f92170b562dd08c59276a2bd.PcLzGLPAefhRwY188QdGqOhj5B6QgOfKyW6o4XSlr-A.YoGYYfztQJ4rqdcllkspxpgL1CjfwaSJ_zzFiDLpgtRZ9pkp64k8umWuzA~741499e6d675be5fe42845cbd16e0434

Analysts' recommendations: LivaNova PLC

02-25	Needham Adjusts Price Target on LivaNova to $81 From $64	MT
12-19	KeyBanc Initiates LivaNova at Overweight With $81 Price Target	MT
25-10-01	LivaNova Shares Fall After Goldman Sachs Downgrade	MT
25-10-01	Goldman Sachs Downgrades LivaNova to Neutral From Buy, Trims Price Target to $55 From $56	MT
25-08-06	LivaNova beats estimates for Q2 revenue, raises FY guidance	RE
25-05-20	Wolfe Upgrades LivaNova to Outperform From Peer Perform, Price Target is $60	MT
25-02-26	Wolfe Research Downgrades LivaNova to Peer Perform From Outperform	MT
24-09-17	Baird Upgrades LivaNova to Outperform From Neutral	MT
24-07-31	Needham Raises LivaNova's Price Target to $75 From $72, Buy Rating Maintained	MT
24-02-27	Barclays Adjusts Price Target on LivaNova to $61 From $57, Keeps Equalweight Rating	MT
24-02-26	Barclays Raises Price Target on LivaNova to $61 From $57, Maintains Equalweight Rating	MT
24-02-22	Baird Adjusts LivaNova's Price Target to $62 From $56, Keeps Neutral Rating	MT
24-02-22	Wolfe Research Adjusts LivaNova's Price Target to $65 From $58, Keeps Outperform Rating	MT
24-02-22	Mizuho Securities Adjusts Price Target on LivaNova to $75 From $70, Maintains Buy Rating	MT
24-02-21	Needham Adjusts Price Target on LivaNova to $72 From $62, Keeps Buy Rating	MT
24-02-20	Mizuho Securities Upgrades LivaNova to Buy From Neutral, Raises Price Target to $70 From $60	MT
23-10-23	Needham Adjusts LivaNova Price Target to $62 From $71, Maintains Buy Rating	MT
23-09-06	HSBC Initiates LivaNova With Hold Rating, Price Target is $52	MT
23-05-08	Barclays Adjusts Price Target on LivaNova to $51 From $45, Maintains Equalweight Rating	MT
23-05-03	Needham Adjusts LivaNova's Price Target to $63 From $77, Keeps Buy Rating	MT
23-04-14	Mizuho Initiates LivaNova at Neutral With $48 Price Target	MT
22-12-21	Barclays Initiates Coverage on LivaNova With Equal Weight Rating, $62 Price Target	MT
22-11-23	Goldman Sachs Adjusts LivaNova's Price Target to $63 From $73, Keeps Buy Rating	MT
22-11-03	Needham Adjusts Price Target on LivaNova to $77 From $88, Maintains Buy Rating	MT
22-08-16	Goldman Sachs Cuts Price Target on LivaNova to $73 From $85, Maintains Buy Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBOTT LABORATORIES					+17.2%
	MEDTRONIC PLC					+13.79%
	CENCORA, INC.					+19.6%
	BECTON, DICKINSON AND COMPANY					+8.14%
	HOYA CORPORATION					+33.6%
	DEXCOM, INC.					+5.74%
	MEDLINE INC.					+40.96%
	WEST PHARMACEUTICAL SERVICES, INC.					+11.89%
	SARTORIUS STEDIM BIOTECH					+18.88%
	Average					+18.87%
	Weighted average by Cap.					+17.66%